Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine add-on for major depressive disorder with inadequate antidepressant response
ACTRN12623001068651Phase 4Recruiting
- Sponsor
- Northern Sydney Local Health District
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esketamine in major depressive disorder (MDD), sponsored by Northern Sydney Local Health District. Primary endpoints: Treatment responder rate by HAM-D 17, Depression severity by QIDS-SR 16 and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12623001068651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001068651.